| Prev Close | 85.80 |
| Open | 85.21 |
| Day Low/High | 84.75 / 87.10 |
| 52 Wk Low/High | 49.96 / 136.02 |
| Volume | 443.41K |
| Avg Volume | 863.40K |
| Exchange | NASDAQ |
| Shares Outstanding | 91.73M |
| Market Cap | 7.77B |
| EPS | -4.80 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Alnylam To Host Fourth Annual "RNAi Roundtable" Webcast Series
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that it plans to host its 4 th annual series of "RNAi Roundtable" webcasts this summer and early fall.
Tesla's Rally Has Died: Stock Falls to Sixth Worst Performer in Russell 1000
It was the seventh best performer in the index during the first half of the year.
Alnylam And Sanofi Genzyme Report Positive Results From Ongoing Phase 2 Open-Label Extension Study With Investigational RNAi Therapeutic Fitusiran In Patients With Hemophilia A And B With Or Without Inhibitors
Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today new positive results from the ongoing...
Alnylam And Sanofi Genzyme Initiate ATLAS Phase 3 Program With Investigational RNAi Therapeutic Fitusiran In Patients With Hemophilia A And B With Or Without Inhibitors
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today the initiation of the ATLAS Phase 3...
Alnylam And Sanofi Genzyme To Present New Clinical Trial Results At The International Society Of Thrombosis And Haemostasis (ISTH) Congress
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced that new results from an ongoing Phase 2...
Alnylam Reports New Positive Clinical Results For Givosiran (ALN-AS1), An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today new positive interim results from Part C, cohorts 1-3, of its ongoing double-blind, randomized, placebo-controlled...
Alnylam CEO, John Maraganore, Named BIO Chair For 2017-2018 Term
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that Chief Executive Officer John Maraganore, Ph.
Alnylam Significantly Expands Patent Portfolio With New Allowances From United States Patent And Trademark Office
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for two patent...
FDA Grants Breakthrough Therapy Designation For Alnylam's Givosiran For The Prophylaxis Of Attacks In Patients With Acute Hepatic Porphyria
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has received Breakthrough Therapy designation from the U.
Alnylam To Webcast Presentation At Jefferies 2017 Healthcare Conference
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Jefferies 2017 Healthcare Conference on Tuesday, June 6, 2017 at...
Biotech Movers: Inovio, Neurocrine, Alnylam
Inovio Pharmaceuticals, Neurocrine Biosciences and Alnylam Pharmaceuticals were among the biotech movers in premarket trading on Wednesday.
Alnylam Pharmaceuticals Prices Public Offering Of Common Stock
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of...
Alnylam Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the commencement of an underwritten public offering of 5,000,000 shares of its common stock.
Biotech Movers: Ionis, Alnylam, Amicus, Minerva
Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Amicus Therapeutics and Minerva Neurosciences were among the biotech movers in premarket trading on Monday.
Alnylam Pharmaceuticals, Inc. Reports Inducement Grant To New Chief Financial Officer
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has granted stock options to Manmeet S.
Alnylam To Webcast Presentations At Upcoming May Investor Conferences
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the Bank of America Merrill Lynch 2017 Healthcare Conference on...
Alnylam Expands Leadership Team With Multiple Experienced Biotech Leaders
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today the appointment of several experienced industry leaders to key leadership roles including: Manmeet S.
Alnylam Pharmaceuticals Reports First Quarter 2017 Financial Results And Highlights Recent Period Activity
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2017, and highlighted recent progress in advancing its pipeline.
Alnylam To Webcast Conference Call Discussing First Quarter 2017 Financial Results
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2017 on Friday, May 5, 2017, before the...
Alnylam Reports Final 24-Month Results From Phase 2 Open-Label Extension Study Of Patisiran, An Investigational RNAi Therapeutic In Development For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today final 24-month results from its Phase 2 open-label extension (OLE) study of patisiran, an investigational RNAi...
The Medicines Company And Alnylam Pharmaceuticals Announce Agreement With FDA On Phase III Clinical Program For Inclisiran
The Medicines Company (NASDAQ:MDCO) and Alnylam Pharmaceuticals, Inc.
Alnylam To Webcast Presentation At 16th Annual Needham Healthcare Conference
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 16 th Annual Needham Healthcare Conference on Wednesday,...
Regenxbio Leads Biotech Movers Ahead of Market's Open
Also on the move were Global Blood Therapeutics, Valeant and Kite Pharma, among others.
The Medicines Company And Alnylam Pharmaceuticals Report Positive Final Results From ORION-1 Phase II Study Of Inclisiran
The Medicines Company (NASDAQ: MDCO) and Alnylam Pharmaceuticals, Inc.
Alnylam Receives European Medicines Agency PRIME Designation For Accelerated Assessment Of Givosiran, An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) has granted access to its Priority Medicines (PRIME) scheme for givosiran...
Alnylam Acknowledges Rare Disease Day By Highlighting Services To Aid In Rare Disease Diagnosis
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today marked the 10 th annual Rare Disease Day by underscoring its commitment to enabling diagnosis for people and caregivers...
Alnylam To Webcast Presentations At Upcoming March Investor Conferences
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the Cowen and Company 37 th Annual Healthcare Conference on...
This Healthy Snack Maker Is One of 5 Stocks Ready for a Major Breakout
Here's how to bank some gains.
